Latest Blood disorders Stories

Just over two years ago a seemingly healthy Eve Haim, mother of 4, including College Complete CEO Dan Haim, was diagnosed with Myelodysplastic Syndrome (MDS), also known as pre-leukemia, which is caused by the failure of bone marrow to produce proper white cells. That summer, Eve began chemotherapy treatments to no avail, and by year’s end received a transplant. Kansas City, KS (PRWEB) April 19, 2012 Just over two years ago a seemingly healthy Eve Haim, mother of 4 including College...

WHITE PLAINS, N.Y., April 19, 2012 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) salutes Carl June, M.D., of University of Pennsylvania School of Medicine, and the members of his team, for the latest recognition of their groundbreaking advances in immunotherapy. Today the Clinical Research Forum announced Dr. June's lab as among its Top 10 Clinical Research Achievement Awards. The awards recognize studies, all published within the last two years, that represent...

WASHINGTON, April 19, 2012 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest organization concerned with the causes and treatment of blood disorders, today released the Blood journal app for iPhone and iPad. Blood is the official Journal of the Society and the most cited peer-reviewed publication in the field. By downloading the free application, users can access First Edition articles, conduct full-text searches, and view listings of articles...

(Ivanhoe Newswire) -- According to a recent study, two related enzymes, phosphoinositide-3 kinase (PI3k) gamma and delta, have been found to have a role in the development of an aggressive childhood leukemia (T-cell acute lymphoblastic leukemia (T-ALL)) that is highly difficult to treat. The study sets the stage for clinical trials by revealing that a dual PI3K gamma/delta inhibitor can prolong survival in a mouse model of the disease and the dual inhibitor can prevent proliferation and...

SEATTLE and SINGAPORE, April 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement pursuant to which CTI would acquire world-wide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus Associated Kinase 2) selective inhibitor that has demonstrated encouraging clinical benefit in phase 1 and 2 clinical studies in...

MONTREAL, April 17, 2012 /PRNewswire/ -The CML Society of Canada commends the Ontario government for the recent decision to add Sprycel (dasatinib) and Tasigna (nilotinib) to the list of CML (chronic myelogenous leukemia) treatments reimbursed in first line, giving patients newly diagnosed with CML more treatment options earlier.  As patient advocates for equal access to all available therapies, the CML Society of Canada feels it is important that governments are aware that it is...

Inhibiting 2 related enzymes significantly improves survival in mouse model of the disease Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes — phosphoinositide-3 kinase (PI3K) gamma and delta — play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat. The study also showed that a dual PI3K gamma/delta inhibitor can significantly prolong survival in a...

KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is...

MONTREAL, April 16, 2012 /PRNewswire/ -- An estimated one in 1,000 women and men has a bleeding disorder. However, 75 percent still receive very inadequate treatment or no treatment at all. What will it take to Close the Gap? To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/world-hemophilia-day----april-17-147623835.html On World Hemophilia Day 2012, the global bleeding disorders community will spread the message to...

Use of new gene-sequencing technology rapidly identifies mutations that lead to drug resistance Through a groundbreaking new gene sequencing technology, researchers have demonstrated that the gene FLT3 is a valid therapeutic target in Acute Myeloid Leukemia, AML, one of the most common types of leukemia. The technique, developed by Pacific Biosciences, allows for the rapid and comprehensive detection of gene mutations in patients with AML. The findings, published online April 15 in...